Oct 19th, 2022
Monday's Late-Breaking Science
Today's Late-Breakers cover vascular interventions, treating arrhythmias and hypertension.
LBS.07. Preventing Limb Loss Through Vascular Interventions and Venous Therapies
Monday, Nov. 7 | 8-9 a.m. | Main Event I
- Best Endovascular Versus Best Surgical Therapy for Patients With Chronic Limb Threatening Ischemia (BEST-CLI) Trial: Clinical Results (BEST-CLI)
- Best Endovascular Versus Best Surgical Therapy for Patients With Chronic Limb Threatening Ischemia (BEST-CLI) Trial: Quality of Life Analyses (BEST-CLI)
- Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With COVID-19: Primary Results of the PREVENT-HD Randomized Clinical Trial (PREVENT-HD)
- A Multicenter Clustered Randomized Trial of a Universal Electronic Health Record-Based Venous Thromboembolism Risk Assessment Model as Integrated Clinical Decision Support for Prevention of Thromboembolism in Hospitalized Medically Ill Patients (IMPROVE Trial)
LBS.08. Treating Atrial and Supraventricular Arrhythmias
Monday, Nov. 7 | 11 a.m.-Noon | Main Event I
- The Impact of “First-Line” Rhythm Therapy on Atrial Fibrillation Progression: The Progressive-AF Trial (PROGRESSIVE-AF)
- Self-Administered Etripamil for Termination of Spontaneous Paroxysmal Supraventricular Tachycardia: Primary Analysis From the Rapid Study (RAPID)
- Efficacy and Safety of Botulinum Toxin Type A for the Prevention of Postoperative Atrial Fibrillation in Cardiac Surgery Patients: Results From the Phase 2 NOVA Study (NOVA)
- Clinical Trial to Evaluate an Atrial Fibrillation Stroke Prevention Shared Decision-Making Pathway (ENHANCE-AF)
LBS.09. Resistant HTN: A Pressure Cooker
Monday, Nov. 7 | 3-4 p.m. | Main Event I
- Top-Line Results of The First-in-Class Aminopeptidase-A Inhibitor Firibastat in Treatment-Resistant Hypertension (FRESH) Study (FRESH)
- Sustained Blood Pressure Lowering Effect With the Dual Endothelin Receptor Antagonist Aprocitentan in Resistant Hypertension: Results From a Randomized, Controlled Study Including a Withdrawal Phase (PRECISION)
- Results From a Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Baxdrostat in Patients With Treatment-Resistant Hypertension (BrigHTN)
- Effect of Radio-Frequency Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs: 6-Month Primary Results From the SPYRALHTN-ON Med Expansion Randomized Trial (SPYRAL HTN-ON)
